Navigation Links
K-V Pharmaceutical Names Thomas McHugh Chief Financial Officer
Date:7/15/2010

ain assets, and the terms of such transactions;
  • the possibility that default on one type or class of the Company's indebtedness could result in cross default under, and the acceleration of, its other indebtedness;
  • the risks that present or future changes in the Board of Directors or management may lead to an acceleration of the Company's bonds or to adverse actions by government agencies or our auditors;
  • if a director of our company, or a shareholder with an ownership interest in our company of 5% or more, is excluded from participating in federal or state health care programs, then HHS may use its discretionary authority to also exclude our company from participation in federal healthcare programs;
  • the risk that the failure to comply with the quantitative listing standards of the New York Stock Exchange, including with respect to minimum share price and public float, could result in delisting of our shares on the New York Stock Exchange, which would harm the market price of the Company's Class A common stock and Class B common stock;
  • the risk that the Company will be unable to engage a successor independent registered public accounting firm promptly or be unable to complete the review of its Annual Report on Form 10-K for its fiscal year ended March 31, 2010 promptly, which would impact the Company's compliance with New York Stock Exchange listing standards, and the Securities Exchange Act of 1934, as amended;
  • delays in retaining successor auditors; and
  • the risks detailed from time-to-time in the Company's filings with the SEC.

  • This discussion is not exhaustive, but is designed to highlight important factors that may impact the Company's forward-looking statements.

    Because the factors referred to above, as well as the statements included elsewhere in this press release, could cause actual results or outcom
    '/>"/>

    SOURCE K-V Pharmaceutical Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
    2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
    6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
    9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/30/2014)... nebulizer is a medical device used for the treatment ... converts liquid medication into mist or aerosol. Thus, the ... patient when inhaled through the mouth or a face ... devices powered by electric current and rechargeable batteries. Factors ... fibrosis and growing number of geriatric population worldwide support ...
    (Date:10/30/2014)... 2014 CTI BioPharma Corp. (CTI) (NASDAQ and MTA: ... September 30, 2014. "During the quarter, ... beginning of 2014 by securing a partner to accelerate the ... market into countries where we do not have a commercial ... this partnership will maximize the value of PIXUVRI for CTI ...
    (Date:10/30/2014)... 2014 Today Eli Lilly and Company (NYSE: ... technology transfer program to increase the global supply of ... effort included Lilly donating manufacturing technology and know-how for ... , India , ... – all MDR-TB ,hot spots., It also served ...
    Breaking Medicine Technology:Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3CTI BioPharma Reports Third Quarter 2014 Financial Results 2CTI BioPharma Reports Third Quarter 2014 Financial Results 3CTI BioPharma Reports Third Quarter 2014 Financial Results 4CTI BioPharma Reports Third Quarter 2014 Financial Results 5CTI BioPharma Reports Third Quarter 2014 Financial Results 6CTI BioPharma Reports Third Quarter 2014 Financial Results 7CTI BioPharma Reports Third Quarter 2014 Financial Results 8CTI BioPharma Reports Third Quarter 2014 Financial Results 9CTI BioPharma Reports Third Quarter 2014 Financial Results 10CTI BioPharma Reports Third Quarter 2014 Financial Results 11CTI BioPharma Reports Third Quarter 2014 Financial Results 12Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4
    ... - Introgen,Therapeutics, Inc. (NASDAQ:INGN) today announced the publication ... survival,pathway impacts the anticancer activity of INGN 241. ... tumor killing effects of,INGN 241 in cell culture ... Introgen and The University of Texas M. D. ...
    ... 2007 - Genmab A/S (CSE: GEN),announced today that ... (HuMax-CD20™) in patients with rheumatoid,arthritis (RA) have been ... Congress of Rheumatology (EULAR). The oral,presentation, which will ... II study with ofatumumab, along with data,from the ...
    Cached Medicine Technology:Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241 2Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241 3
    (Date:10/30/2014)... comes to heart disease, a new study finds women are ... symptoms that spell trouble. "The main danger is that ... or advanced stage of heart disease, there are simply fewer ... and research fellow at the Harvard School of Public Health, ... Foundation of Canada. In the study, researchers talked to ...
    (Date:10/30/2014)... Amy Norton HealthDay Reporter ... a common plastics, chemical during pregnancy may have effects on ... Researchers found that baby boys born to moms with greater ... shorter anogenital distance -- the space between the genitals and ... considered a marker of exposure to androgens ("male" hormones) during ...
    (Date:10/30/2014)... Many U.S. colleges have indoor tanning salons on ... risk for skin cancer, researchers report. Tanning ... so colleges should adopt tanning-free policies, to help ... health efforts are needed to raise university administration ... indoor tanning poses to young adults in order ...
    (Date:10/30/2014)... opinions about the Affordable Care Act are sharply divided ... voters are strongly in favor of the Affordable Care ... Democrats want the next Congress to move ahead with ... current law, while 44 percent want to expand the ... want the law repealed, and 27 percent want it ...
    (Date:10/30/2014)... respects the fact that a patient,s body is ... Over a third of cancer patients experience psychosocial ... conditions. And, increasingly, care providers are exploring phone- ... mental health challenges. A University of Colorado Cancer ... Psycho-Oncology asks an important question: after decades ...
    Breaking Medicine News(10 mins):Health News:Women Often Ignore Signs of Heart Trouble 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2Health News:Voters' Views on Obamacare Split Along Party Lines 2Health News:Decades of research: Effectiveness of phone counseling for cancer patients still unknown 2
    ... day to analysis and expert thought, they may be able ... of the precise type of brain tumour they face. Now ... technique that can give a preliminary analysis of the precise ... the brain and nervous system and they account for 20% ...
    ... Rosemont, Ill. - June 17, 2008- Current protein recommendations ... newer research indicates that many adults may benefit from ... presented in a supplement in the May issue of ... describing the conclusions of a Protein Summit ...
    ... on invasion and migration in colorectal cancer cell line. This ... performed by a team led by Professor Ji-Kun Li from ... article to be published on April 21, 2008 in the ... of the main causes of cancer-related death in the world. ...
    ... 17 XTENT, Inc.,(Nasdaq: XTNT ) today announced ... the current issue of EuroIntervention was recognized by the,journal,s ... submitted to the,journal this past winter. Lutz Buellesfeld, M.D., ... of the study,s investigators, received,an award in conjunction with ...
    ... Ala., June 17 Emageon Inc.,(Nasdaq: EMAG ... for hospitals, healthcare networks and imaging facilities announced,today ... present at the,Jefferies 2nd Annual Healthcare Conference on ... 24th at 8:30 AM ET. The presentation will ...
    ... 17 Nutrition 21, Inc.,(Nasdaq: NXXI ), ... consumers manage blood sugar levels, improve cardiovascular health,enhance ... Skin,Rejuvenation(TM) a new Iceland Health-branded product. Skin Rejuvenation ... capsule form,designed to reduce, at the cellular level, ...
    Cached Medicine News:Health News:Wavelets crunch through doctors' day long struggle to diagnose brain tumors 2Health News:Is it time to revisit the current protein recommendations? 2Health News:Is it time to revisit the current protein recommendations? 3Health News:XTENT Announces CUSTOM I Data Receives Recognition from EuroIntervention 2Health News:XTENT Announces CUSTOM I Data Receives Recognition from EuroIntervention 3Health News:Nutrition 21 Introduces New Product: Iceland Health Skin Rejuvenation(TM) 2Health News:Nutrition 21 Introduces New Product: Iceland Health Skin Rejuvenation(TM) 3
    Adhesive tape sheets for sealing multiwell plates and blocks;...
    Microwell Plate Accessories...
    DMSO-resistant microplate sealing film...
    Amplification Tape 96 featuring 3M adhesive technology. Good optical quality. Minimal autofluorescence. Certified RNase and DNase free....
    Medicine Products: